Cargando…

2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis

BACKGROUND: Antimicrobials disrupt the gut microbiota by reducing gut microbiome diversity and quantity. Galleria mellonella provides an invertebrate model that is inexpensive, easy to maintain, and does not require specialized equipment. This study investigated the feasibility of using G. mellonell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alnezary, Faris S, Rashid, Tasnuva, Begum, Khurshida, Carlson, Travis J, Gonzales-Luna, Anne J, Alam, M Jahangir, Garey, Kevin W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809783/ http://dx.doi.org/10.1093/ofid/ofz360.2259

Ejemplares similares

2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth
por: Alnezary, Faris, et al.
Publicado: (2020)

784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106
por: Almutairi, Masaad, et al.
Publicado: (2020)

2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes
por: Carlson, Travis J, et al.
Publicado: (2019)

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor
por: Garey, Kevin W, et al.
Publicado: (2019)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh
por: Alam, M Jahangir, et al.
Publicado: (2017)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

2378. Corticosteroid Use Prevents Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use Among Hospitalized Patients
por: Carlson, Travis J, et al.
Publicado: (2019)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

802. Proton Pump Inhibitors Increase Clostridioides difficile Disease Severity Controlling for Infecting Strains
por: Fallatah, Saad, et al.
Publicado: (2020)

PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255
por: Gonzales-Luna, Anne J., et al.
Publicado: (2020)

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection
por: Garey, Kevin W, et al.
Publicado: (2021)

Revision and reannotation of the Halomonas elongata DSM 2581(T) genome
por: Pfeiffer, Friedhelm, et al.
Publicado: (2017)

2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection
por: Dotson, Kierra M, et al.
Publicado: (2019)

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial( )
por: Garey, Kevin W, et al.
Publicado: (2022)

Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use
por: Carlson, Travis J, et al.
Publicado: (2021)

Comparison of Risk Stratification Approaches to Identify Patients with Clostridioides difficile Infection at Risk for Multidrug-Resistant Organism Gut Microbiota Colonization
por: Zasowski, Evan J., et al.
Publicado: (2023)

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects
por: Garey, Kevin W, et al.
Publicado: (2020)

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection
por: McPherson, Jacob, et al.
Publicado: (2022)

510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals
por: Alam, M Jahangir, et al.
Publicado: (2018)

521. Investigating the Gram-Positive Selective Spectrum of Ibezapolstat, a First-in-Class DNA Polymerase IIIC (Pol IIIC) Inhibitor
por: Jahangir Alam, M, et al.
Publicado: (2022)

1720. Isolation and Characterization of Candida auris From an Active Surveillance System in Texas
por: Alam, M Jahangir, et al.
Publicado: (2019)

2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital
por: Begum, Khurshida, et al.
Publicado: (2019)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

620. Pharmacokinetic-Pharmacodynamic Analysis of Oral Vancomycin and Gut Microbiome Changes in Healthy Volunteers: an Exploratory Study
por: Jo, Jinhee, et al.
Publicado: (2022)

157. A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins
por: Jo, Jinhee, et al.
Publicado: (2021)

2063. Elucidating the Gram-Positive Selective Spectrum Activity of Ibezapolstat; Secondary Analysis from the phase 2a trial
por: Lancaster, Chris, et al.
Publicado: (2023)

Dysbiosis of the Gut Microbiome in Lung Cancer
por: Zhuang, He, et al.
Publicado: (2019)

Dysbiosis of skin microbiome and gut microbiome in melanoma progression
por: Mekadim, Chahrazed, et al.
Publicado: (2022)

A blueprint of ectoine metabolism from the genome of the industrial producer Halomonas elongata DSM 2581(T)
por: Schwibbert, Karin, et al.
Publicado: (2011)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

Current Perspectives on Gut Microbiome Dysbiosis and Depression
por: Capuco, Alexander, et al.
Publicado: (2020)

Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant Recipients
por: Swarte, J. Casper, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ejd79blvbearqcrbjdbo8k3qnk